Department of Laboratory Diagnostics, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Central Laboratory of Hematology and Oncology, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Int J Hematol. 2021 Mar;113(3):337-343. doi: 10.1007/s12185-021-03085-y. Epub 2021 Jan 27.
B-cell acute lymphoblastic leukemia (B-ALL) is a hematologic malignancy of B-type lymphoid precursor cells. Minimal/measurable residual disease (MRD) is an important prognostic factor for B-ALL relapse. Traditional flow cytometry detection mainly relies on CD19-based gating strategies. However, relapse of CD19-negative B-ALL frequently occurs in patients who receive cellular and targeted therapy. This review will summarize the technical aspects of standard MRD assessment in B-ALL by flow cytometry, and then discuss the challenges of MRD strategies to deal with the scenario of CD19 negative or dim B-ALL relapse.
B 细胞急性淋巴细胞白血病（B-ALL）是一种 B 型淋巴样前体细胞的血液系统恶性肿瘤。微小残留病（MRD）是 B-ALL 复发的一个重要预后因素。传统的流式细胞术检测主要依赖于基于 CD19 的门控策略。然而，接受细胞和靶向治疗的患者中经常会发生 CD19 阴性的 B-ALL 复发。本文将总结通过流式细胞术对 B-ALL 进行标准 MRD 评估的技术方面，然后讨论 MRD 策略应对 CD19 阴性或弱表达 B-ALL 复发情况的挑战。
